Hualin Helen Li

Dr. Hualin Helen Li


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2021 in Vaccine
Verified
Journal Article
Closed access
HLHualin Helen Li
Hualin Helen Li
MMMorgan A. Monslow
Morgan A. Monslow
DFDaniel C. Freed
Daniel C. Freed
DCDan Chang
Dan Chang
FLFengsheng Li
Fengsheng Li
TFTong-Ming Fu
Tong-Ming Fu

9 November 2017 in PLOS ONE
Verified
Journal Article
Open access
PDF file
HLHualin Helen Li
Hualin Helen Li
CCCheryl Callahan
Cheryl Callahan
MCMichael Citron
Michael Citron
ZWZhiyun Wen
Zhiyun Wen
STSinoeun Touch
Sinoeun Touch
AEAmy Espeseth
Amy Espeseth
Respiratory syncytial virus (RSV) is a leading cause of serious lower respiratory tract disease in young children and older adults throughout the world. Prevention of severe RSV disease through active immunization is optimal but no RSV vaccine has been licensed so far. Immune mechanisms of protection against RSV infection in humans have not been fully established, thus a comprehensive characterization of virus-specific immune responses in a relevant animal model will be beneficial in defining correlates of protection. In this study, we infected juvenile naive AGMs with RSV A2 strain and longitudinally assessed virus-specific humoral and cellular immune responses in both peripheral blood and the respiratory tract. RSV viral loads at nasopharyngeal surfaces and in the lung peaked at around day 5 following infection, and then largely resolved by day 10. Low levels of neutralizing antibody titers were detected in serum, with similar kinetics as RSV fusion (F) protein-binding IgG antibodies. RSV infection induced CD8+, but very little CD4+, T lymphocyte responses in peripheral blood. Virus-specific CD8+ T cell frequencies were ~10 fold higher in bronchoaveolar lavage (BAL) compared to peripheral blood and exhibited effector memory (CD95+CD28-) / tissue resident memory (CD69+CD103+) T (TRM) cell phenotypes. The kinetics of virus-specific CD8+ T cells emerging in peripheral blood and BAL correlated with declining viral titers, suggesting that virus-specific cellular responses contribute to the clearance of RSV infection. RSV-experienced AGMs were protected from subsequent exposure to RSV infection. Additional studies are underway to understand protective correlates in these seropositive monkeys.

11 June 2023 in Journal of Pharmaceutical and Biomedical Analysis
Verified
Journal Article
Closed access
HLHualin Helen Li
Hualin Helen Li
JXJenny Xu
Jenny Xu
LHLi He
Li He
LDLynne Ireland Denny
Lynne Ireland Denny
RRRichard R. Rustandi
Richard R. Rustandi
ZZZhi-Qiang Zhang
Zhi-Qiang Zhang

4 December 2018 in BMC Infectious Diseases
Verified
Journal Article
Open access
PDF file
ZCZHIFENG CHEN
ZHIFENG CHEN
KCKara S. Cox
Kara S. Cox
ATAimin Tang
Aimin Tang
JRJeanette Roman
Jeanette Roman
MFMalorie Fink
Malorie Fink
KVKalpit Vora
Kalpit Vora
Community-acquired pneumonia is a leading infectious cause of hospitalization. A few vaccines exist to prevent pneumococcal disease in adults, including a pneumococcal polysaccharide unconjugated vaccine and a protein conjugated polysaccharide vaccine. Previous studies on the human immune response to the unconjugated vaccine showed that the vaccine boosted the existing memory B cells. In the present study, we investigated the human B cell immune response following pneumococcal polysaccharide conjugate vaccination. Plasmablast B cells from a pneumococcal polysaccharide conjugate vaccinee were isolated and cloned for analysis. In response to primary vaccination, identical sequences from the plasmablast-derived antibodies were identified from multiple B cells, demonstrating evidence of clonal expansion. We evaluated the binding specificity of these human monoclonal antibodies in immunoassays, and tested there in vitro function in a multiplexed opsonophagocytic assay (MOPA). To characterize the plasmablast B cell response to the pneumococcal conjugated vaccine, the germline usage and the variable region somatic hypermutations on these antibodies were analyzed. Furthermore, a serotype 4 polysaccharide-specific antibody was tested in an animal challenge study to explore the in vivo functional activity. The data suggests that the pneumococcal polysaccharide conjugate vaccine boosted memory B cell responses, likely derived from previous pneumococcal exposure. The majority of the plasmablast-derived antibodies contained higher numbers of variable region somatic hypermutations and evidence for selection, as demonstrated by replacement to silent ratio’s (R/S) greater than 2.9 in the complementarity-determining regions (CDRs). In addition, we found that VH3/JH4 was the predominant germline sequence used in these polysaccharide-specific B cells. All of the tested antibodies demonstrated narrow polysaccharide specificity in ELISA binding, and demonstrated functional opsonophagocytic killing (OPK) activity in the MOPA assay. The in-vivo animal challenge study showed that the tested serotype 4 polysaccharide-specific antibody demonstrated a potent protective effect when administered prior to bacterial challenge. The findings on the pneumococcal polysaccharide conjugate vaccine responses from a vaccinated subject reported in this study are similar to previously published data on the pneumococcal polysaccharide unconjugated vaccine responses. In both vaccine regimens, the pre-existing human memory B cells were expanded after vaccination with preferential use of the germline VH3/JH4 genes.

19 March 2025 in Vaccines
Verified
Journal Article
Open access
PDF file
KFKatrina Feller
Katrina Feller
HNHesham Nawar
Hesham Nawar
LSLiping Song
Liping Song
AAAmanda Abrams
Amanda Abrams
LSLiang Shang
Liang Shang
HLHualin Helen Li
Hualin Helen Li
Background/Objectives: Potency is a critical quality attribute for vaccine development as well as clinical drug product (DP) lot release and stability testing. Animal studies have the potential to offer conclusive insights about the potency of vaccines by demonstrating technical relevance with respect to the hypothesized vaccine mode of action. However, animal studies are expensive, time-consuming, labor intensive, and, most importantly, involve the use of animals. Therefore, alternative in vitro potency assays should be explored. Methods: In this study, female BALB/c mice were immunized intramuscularly with various doses of a respiratory syncytial virus (RSV) mRNA vaccine V171 lots at day 0 and day 21. Vaccine-elicited immune responses were determined by ELISA (post-dose 1) and neutralizing assay (post-dose 2). These vaccine lots were also tested in a cell-based relative potency assay in which the ability of each lot to express the RSV F protein in Hep G2 cells was measured against a reference standard. Results: Effective Dose 50s (ED50s) of the vaccine lots were determined with probit models based on dichotomized ELISA or neutralizing titers. Statistical analysis demonstrated that the post-dose 2 neutralizing ED50 correlates with cell-based relative potency (Pearson’s correlation test ln (RP) and ln (ED50): correlation coefficient = −0.82; p-value = 0.047). Conclusions: These data merit the use of a cell-based potency assay to replace the animal study to support V171 vaccine development and to use for DP lot release and stability testing. This study also establishes proof-of-concept of using cell-based potency assays as an alternative to animal immunogenicity studies for mRNA-based vaccines.

20 April 2026 in Journal of Pharmaceutical and Biomedical Analysis
Verified
Journal Article
Closed access
ASAlyssa - Alyssa Stiving
Alyssa - Alyssa Stiving
GDGeethanjali Dornadula
Geethanjali Dornadula
BRBenjamin W. Roose
Benjamin W. Roose
AGAriel Gonzalez
Ariel Gonzalez
MWMelissa C. Whiteman
Melissa C. Whiteman
XLXuanwen Li
Xuanwen Li